We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Genetic analysis specialist Sequenom nets $92mm in public offer
08 Jul 2008
Executive Summary
Sequenom (platforms for genetic research and molecular diagnostics) netted $92mm through the follow-on public sale of 6.3mm shares (including the overallotment) at $15.50 each. The company will put the money towards developing noninvasive diagnostics that use its nucleic acid analysis system MassARRAY. Under a license from the Chinese University of Hong Kong, Sequenom is initially focusing on prenatal testing to identify fetal gene and chromosome abnormalities.
Deal Industry
Research, Analytical Equipment & Supplies
In Vitro Diagnostics
Molecular Diagnostics & Genetic Testing
Deal Status
Final
Deal Type
Financing
FOPO
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?